How big is BioMarin Pharmaceutical, Inc.?

As of Jun 18, BioMarin Pharmaceutical, Inc. has a market capitalization of $10.55 billion, with net sales of $2.92 billion and a net profit of $523.88 million for the latest four quarters. The company reported shareholder's funds of $5.66 billion and total assets of $6.99 billion as of December 2024.

As of Jun 18, BioMarin Pharmaceutical, Inc. has a market capitalization of 10,547.66 million, categorizing it as a Mid Cap company.<BR><BR>As of Jun 18, the company reported net sales of 2,921.86 million and a net profit of 523.88 million for the latest four quarters ending in March 2025, December 2024, September 2024, and June 2024.<BR><BR>As of December 2024, the company's balance sheet shows shareholder's funds of 5,657.99 million and total assets of 6,988.94 million.

What does BioMarin Pharmaceutical, Inc. do?

BioMarin Pharmaceutical, Inc. is a biotechnology company that develops and commercializes pharmaceuticals for various diseases. As of March 2025, it reported net sales of $733 million and a market cap of approximately $10.55 billion.

Overview:<BR>BioMarin Pharmaceutical, Inc. is a biotechnology company that develops and commercializes pharmaceuticals for various diseases and medical conditions, operating within the Pharmaceuticals & Biotechnology industry and classified as a mid-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 733 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 186 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 10,547.66 Million (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 20.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.11 <BR>Return on Equity: 9.49% <BR>Price to Book: 1.82<BR><BR>Contact Details:<BR>Address: 105 Digital Dr, NOVATO CA: 94949-8703 <BR>Tel: 1 415 5066700 <BR>Fax: 1 415 3827889 <BR>Website: http://www.bmrn.com/

Should I buy, sell or hold BioMarin Pharmaceutical, Inc.?

Who are in the management team of BioMarin Pharmaceutical, Inc.?

As of March 2022, the management team of BioMarin Pharmaceutical, Inc. includes CEO Jean-Jacques Bienaime and Lead Independent Director Richard Meier, along with independent directors Elizabeth Anderson, Willard Dere, Michael Grey, and Elaine Heron.

As of March 2022, the management team of BioMarin Pharmaceutical, Inc. includes Mr. Jean-Jacques Bienaime, who serves as the Chairman of the Board and Chief Executive Officer. The board also features Mr. Richard Meier as the Lead Independent Director, along with independent directors Ms. Elizabeth Anderson, Dr. Willard Dere, Mr. Michael Grey, and Dr. Elaine Heron.

Is BioMarin Pharmaceutical, Inc. technically bullish or bearish?

As of October 3, 2025, BioMarin Pharmaceutical, Inc. shows a mildly bearish technical trend with mixed signals across indicators, underperforming the S&P 500 year-to-date by -15.40% compared to its 14.18% gain.

As of 3 October 2025, the technical trend for BioMarin Pharmaceutical, Inc. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The Bollinger Bands show a mildly bearish trend in both weekly and monthly time frames. Daily moving averages are bearish, and the KST is mildly bullish on a weekly basis but bearish monthly. The Dow Theory suggests a mildly bullish trend weekly, with no trend monthly.<BR><BR>In terms of performance, the stock has underperformed against the S&P 500 across multiple periods, with a year-to-date return of -15.40% compared to the S&P 500's 14.18%, and a one-year return of -20.00% versus 17.82% for the index. Overall, the current technical stance is mildly bearish, reflecting mixed signals across different indicators.

Is BioMarin Pharmaceutical, Inc. overvalued or undervalued?

As of October 17, 2025, BioMarin Pharmaceutical, Inc. is fairly valued with a P/E ratio of 20 and a low PEG ratio of 0.14, but it has underperformed the S&P 500 significantly, with a year-to-date return of -18.93% compared to the index's 13.30%.

As of 17 October 2025, the valuation grade for BioMarin Pharmaceutical, Inc. moved from very attractive to fair. The company appears to be fairly valued given its current metrics. The P/E ratio stands at 20, while the EV to EBITDA ratio is 14.21, and the PEG ratio is notably low at 0.14, indicating potential growth relative to its price.<BR><BR>In comparison to its peers, BioMarin's P/E ratio of 15.17 is lower than Illumina, Inc. at 19.09 and Elanco Animal Health, Inc. at 19.25, suggesting it is more attractively priced within its industry. Despite this, the company has underperformed significantly against the S&P 500, with a year-to-date return of -18.93% compared to the index's 13.30%. This trend continues over longer periods, with a three-year return of -39.98% versus the S&P 500's 81.19%, reinforcing the notion that while the stock may be fairly valued, it faces challenges in delivering returns.